Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 7/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176372 | 0.94 | ADRB2 (0.41) | ADRB2ADRB1ADRB3ATMTSHR | |
| SCHEMBL618225 | 0.91 | — | — | |
| SCHEMBL6178131 | 0.90 | THRB (0.41) | TSHRCA1CA2THRB | |
| SCHEMBL6178964 | 0.88 | THRB (0.47) | TSHRCA1CA2THRB | |
| SCHEMBL6132441 | 0.85 | — | — | |
| SCHEMBL27689281 | 0.83 | THRB (0.42) | TSHRCA1CA2THRB | |
| SCHEMBL8537817 | 0.81 | THRB (0.40) | TSHRCA1CA2THRB | |
| SCHEMBL8724680 | 0.80 | ADRB2 (0.45) | ADRB2ADRB1ADRB3ATMTSHR | |
| SCHEMBL8724684 | 0.80 | ADRB2 (0.45) | ADRB2ADRB1ADRB3ATMTSHR | |
| SCHEMBL6178476 | 0.79 | ADRB2 (0.35) | ADRB2ADRB1ADRB3ATMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117716292-A | Enhanced EUV photoresist and method of using the same | 亚历克斯·P·G·罗宾逊 | 2024-03-15 | — | — | CN | claimed |
| WO-2024010706-A1 | ENHANCED EUV MATERIALS, PHOTORESISTS AND METHODS OF THEIR USE | ROBINSON ALEX P G (GB) | 2024-01-11 | — | — | WO | claimed |
| WO-2023229985-A1 | ENHANCED EUV PHOTORESISTS AND METHODS OF THEIR USE | ROBINSON ALEX P G (GB) | 2023-11-30 | — | — | WO | claimed |
| CN-109312158-B | Polysulfonamide redistribution compositions and methods of use thereof | 丹尼尔·J·纳罗奇 | 2022-02-11 | — | — | CN | claimed |
| CN-109312158-A | Polysulfonamide redistribution compositions and methods of use thereof | 丹尼尔·J·纳罗奇 | 2019-02-05 | — | — | CN | claimed |
| CN-107406392-A | Composition of matter and molecular resists made therefrom | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2017-11-28 | — | — | CN | claimed |
| CN-104884423-B | methanofullerene | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2017-11-17 | — | — | CN | claimed |
| WO-2017196953-A1 | POLYSULFONAMIDE REDISTRIBUTION COMPOSITIONS AND METHODS OF THEIR USE | NAWROCKI, DANIEL, J. (US) | 2017-11-16 | — | — | WO | claimed |
| US-20170329222-A1 | Polysulfonamide Redistribution Compositions and Methods of Their Use | NAWROCKI DANIEL J (US) | 2017-11-16 | — | — | US | claimed |
| CN-107087426-A | two-step photoresist composition and method | 亚历克斯·菲利普·格雷厄姆·罗宾逊 | 2017-08-22 | — | — | CN | claimed |
| US-20140134843-A1 | Methanofullerenes | IRRESISTIBLE MATERIALS LTD (GB) | 2014-05-15 | — | — | US | claimed |
| CN-102203087-A | Heterocyclically substituted anilinopyrimidines as fungicides | BAYER CROPSCIENCE AG | 2011-09-28 | — | — | CN | claimed |
| EP-2331533-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | claimed |
| WO-2010025850-A1 | HETEROCYCLICALLY SUBSTITUTED ANILINOPYRIMIDINES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| US-20030130398-A1 | Soft polymeric compounds including metal oxide fillers | BRIDGESTONE CORPORATION | 2003-07-10 | — | — | US | claimed |
| US-6369166-B1 | PLASTICIZED; TENSILE AND TEAR STRENGTH; ELONGATION; HIGH DAMPING; ETHYLENE-MALEIC ANHYDRIDE COPOLYMER REACTED WITH PRIMARY AMINE | BRIDGESTONE CORPORATION (JP) | 2002-04-09 | — | — | US | claimed |
| US-6207763-B1 | A COPOLYMER OF SUBSTITUTED OR UNSUBSTITUTED 1-20 ALKYL GROUP DISUBSTITUTED ETHYLENE-MALEIMIDE COPOLYMER(A REACTION PRODUCT OF DISUBTITUTED ETHYLENE-MALEIC ANHYDRIDE IMIDIZED WITH PRIMARY AMINE) IS A PLASTICIZER FOR RUBBER; HIGH DAMPING | BRIDGESTONE CORPORATION (JP) | 2001-03-27 | — | — | US | claimed |
| US-6191217-B1 | REACTING POLY(ALKYL VINYLETHER-CO-MALEIMIDE) POLYMER WITH MALEATED POLYALKYLENE AND ALKYL DIAMINE UNDER SUBSTANTIALLY DRY CONDITIONS SUFFICIENT TO FORM POLYALKYLENE GRAFTED POLY(ALKYL VINYLETHER-CO-MALEIMIDE) POLYMER | BRIDGESTONE CORPORATION (JP) | 2001-02-20 | — | — | US | claimed |
| US-6133354-A | MIXING A POLY(DIALKYLSUBSTITUTED ETHYLENE-CO-MALEIMIDE) POLYMER SUCH AS POLYISOBUTYLENE-CO-MALEIMIDE, AND PLASTICIZERS OR EXTENDERS WITHIN A NON-VULCANIZED THERMOPLASTIC ELASTOMER TO FORM A DAMPING GEL; TENSILE STRENGTH AND TEAR STRENGTH | BRIDGESTONE CORPORATION (JP) | 2000-10-17 | — | — | US | claimed |
| EP-0955319-A1 | Soft compounds derived from polypropylene grafted disubstituted ethylene-maleimide copolymers | Bridgestone Corporation (JP) | 1999-11-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140134843-A1 | Methanofullerenes | WASF2, ERCC4, TUFM | ADRB2 3095/4885ADRB1 4046/4885ADRB3 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.